News articles about Medifast (NYSE:MED) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medifast earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news headlines about the specialty retailer an impact score of 46.2553380095549 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Medifast stock skyrockets 13 percent to $50 per share after earnings beat Wall Street estimates (finance.yahoo.com)
- Medifast, Inc.: Gathering momentum, can it sustain its performance? (finance.yahoo.com)
- Medifast’s 2Q revenue exceeds expectations (thedailyrecord.com)
- Medifast Q2 2017 Revenue Exceeds Company Guidance (directsellingnews.com)
- Edited Transcript of MED earnings conference call or presentation 8-Aug-17 8:30pm GMT (finance.yahoo.com)
Several research analysts have recently weighed in on the company. BidaskClub upgraded Medifast from a “strong sell” rating to a “sell” rating in a research note on Friday. Sidoti lowered Medifast from a “buy” rating to a “neutral” rating in a report on Tuesday, May 2nd.
Medifast (NYSE:MED) traded up 2.25% during midday trading on Friday, hitting $50.87. The company had a trading volume of 174,473 shares. Medifast has a 1-year low of $35.55 and a 1-year high of $51.07. The firm has a market capitalization of $606.88 million, a P/E ratio of 25.56 and a beta of 0.48. The company has a 50 day moving average price of $42.47 and a 200 day moving average price of $43.33.
Medifast (NYSE:MED) last released its earnings results on Tuesday, August 8th. The specialty retailer reported $0.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.10. Medifast had a net margin of 10.01% and a return on equity of 29.92%. The business had revenue of $75.70 million for the quarter, compared to analyst estimates of $71.96 million. During the same period last year, the company posted $0.63 EPS. The business’s revenue was up 6.5% on a year-over-year basis. Equities research analysts forecast that Medifast will post $2.12 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 9th. Shareholders of record on Friday, June 23rd were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend was Wednesday, June 21st. Medifast’s dividend payout ratio (DPR) is 64.32%.
COPYRIGHT VIOLATION NOTICE: “Medifast (NYSE:MED) Earns Daily News Sentiment Rating of 0.20” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-medifast-inc-nysemed-stock-price-updated.html.
Medifast Company Profile
Medifast, Inc is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins.
Receive News & Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related companies with MarketBeat.com's FREE daily email newsletter.